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These findings determined that the eye wash treatment 
was not responsible for reducing MMP-9 levels, ultimately 
reducing dry eye symptoms. 
• May indicate the need for a more standardized or 
supervised method of performing the eye wash
• Tear volume collected may be too dilute to allow 
sufficient data analysis
• More definitive conclusions could result from a similar 
study performed on a larger sample size
• Suggests a new and easily accessible treatment 
alternative for dry eye that could be more 
systematically explored in the long term
• Further stratification may reveal a relationship 
between certain subgroups and dry eye severity 
Dry eye is a common cause of people seeking medical 
attention for their eyes, and its multifactorial nature 
makes it difficult to diagnose and manage.1
• During sleep, the ocular surface becomes inflammatory 
to help maintain overall eye health.2
• However, it is possible that the inflammation may be 
dysregulated and linked to the development of dry eye 
disease. 
• Neutrophils are released as an immune response and 
secrete matrix metalloprotease-9 (MMP-9), which 
degrades the collagen of epithelial cells and further 
disrupts the tear film.3,4
• MMP-9 activity can indicate inflammation, damage, and 
other ocular abnormalities. 
• The overall purpose was to strengthen our 
understanding of the pathogenesis of dry eye disease 
while validating a cost-effective and simple method 
for managing symptoms.
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Matrix metalloprotease-9 (MMP-9) degrades the collagen 
of epithelial cells and further disrupts the tear film. MMP-
9 activity can indicate inflammation, damage, and other 
ocular abnormalities. 
• The data did not show a significant correlation between 
MMP-9 concentration and dry eye symptoms after the 
eye wash performed. 
• The normal treatment group showed a decrease in 
MMP-9 levels.
• A significant difference was observed in the dry eye 
control group before and after treatment, more so than 
in the treatment group.
• Normalization to total protein vs. MMP-9 concentration 
alone projects slightly different results.
Materials and Methods
Human Active MMP-9 Fluorokine E ELISA assay
Enzyme-linked immunosorbent assay (ELISA) quantified 
MMP-9 concentration and activity in the tear supernatant 
samples
Relatively sensitive and
measures both activation 
and concentration of 
enzymes
1. Protein Capture
2. Detection of antibody 
3. Conjugate
4. Addition of Substrate
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1. Subjects performed eye wash on both eyes immediately upon awakening
2. Brought tear samples to clinic on Visits 2, 3, and 4
3. Supernatant from eye wash was collected for protein analysis
BCA Rapid Gold assay
Quantifies total protein 













Subjects perform eye wash at 
beginning and end of month
Subjects perform eye wash daily 
for a month
MMP-9 concentration for normal and dry eye groups normalized to total protein levels.
Normal control: Normal treatment: Dry control: Dry treatment: 
p= 0.66 p=0.34 p= 0.09 p=0.17
MMP-9 Concentration across all groups without normalization
Comparing MMP-9 Concentration between 



































































*Ratio of MMP-9 protein to normalization 
control performed to quantify amount of 
MMP-9 in each sample.
V1 V1.1 V1.2 V2 V2.1 V3 V4
Screening Baseline Midway Final
Washout Randomization
Eye Wash Begins
